MedTrace Logo

Phase 1 Study of Anti-OX40 in Patients With Advanced Cancer

NCT01644968 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-05-17

No results posted yet for this study

Summary

This study is designed to determine the safety and highest tolerated dose of anti-OX40 in patients with advanced cancer.

Conditions

Interventions

DRUG

Cohort 1 anti-OX40

0.1 mg/kg anti-OX40 on days 1, 3, and 5

DRUG

Cohort 2 anti-OX40

.4 mg/kg anti-OX40 on days 1, 3, and 5

DRUG

Cohort 3 anti-OX40

2.0 mg/kg anti-OX40 on days 1, 3, and 5

BIOLOGICAL

Tetanus Day 29

Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29

BIOLOGICAL

Tetanus Day 1

Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.

BIOLOGICAL

KLH Day 1

1 mg KLH in 1 cc diluent subcutaneously on Day 1.

BIOLOGICAL

KLH Day 29

1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.

Sponsors & Collaborators

  • Providence Health & Services

    lead OTHER

Principal Investigators

  • Brendan Curti, MD · Providence Health & Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2009-05-31
Completion
2017-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01644968 on ClinicalTrials.gov